Examining the Completeness of Breast Cancer Pathology Reports Registered in the Population-based Cancer Registration System and Spatial Analysis of the Incidence of this Cancer in Iran in 2016
Zeynab Moradian Haft Cheshmeh, M. Asadi-lari, Ali Motlagh, A. Ostovar
{"title":"Examining the Completeness of Breast Cancer Pathology Reports Registered in the Population-based Cancer Registration System and Spatial Analysis of the Incidence of this Cancer in Iran in 2016","authors":"Zeynab Moradian Haft Cheshmeh, M. Asadi-lari, Ali Motlagh, A. Ostovar","doi":"10.5812/ijcm-137092","DOIUrl":null,"url":null,"abstract":"Background: Breast cancer (BC) is a leading cause of cancer-related deaths among women worldwide, and its incidence has increased in Iran over recent years. Objectives: In this study, we aimed at assessing the completeness of BC pathology reports in the population-based cancer registration system and perform a spatial analysis of the incidence of this cancer in Iran in 2016 to help policymakers develop targeted interventions. Methods: We conducted a retrospective descriptive analysis, using secondary data from the Integrated Cancer Information Management System, and obtained 13789 BC pathology reports from all provinces in Iran in 2016. Pathology data, including tumor type, tumor site, tumor size, pathologic T stage, pathologic N stage, and tumor grade were examined for completeness by age group. Results: Pathology reports from 4000 women with BC in 2016 from across all provinces of Iran were selected for this study. The completeness of tumor type, tumor site, tumor size, pathologic T stage, pathologic N stage, and tumor grade increased with aging. In addition, the completeness of pathology reports varied across different variables. Accordingly, the tumor grade and pathologic T stage had the highest and lowest completeness rates (100 % versus 27.4%), respectively. Spatial analysis revealed significant high-risk areas for BC incidence, including Isfahan, Markazi, Chaharmahal and Bakhtiari, and Kohgiluyeh and Boyer-Ahmad provinces in central Iran. In contrast, North Khorasan was identified as a low-risk area. Conclusions: Considering the incompleteness of the pathology report in most of the tumor variables in the BC registry, we recognize the gaps to improve pathology data. To ensure effective interventions for BC control, tailored preventive measures are needed, particularly for high-risk areas. Continuous evaluation and data completion, including standard cellular pathology reports, are necessary for accurate BC control in Iran.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":"29 1","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2023-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/ijcm-137092","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Breast cancer (BC) is a leading cause of cancer-related deaths among women worldwide, and its incidence has increased in Iran over recent years. Objectives: In this study, we aimed at assessing the completeness of BC pathology reports in the population-based cancer registration system and perform a spatial analysis of the incidence of this cancer in Iran in 2016 to help policymakers develop targeted interventions. Methods: We conducted a retrospective descriptive analysis, using secondary data from the Integrated Cancer Information Management System, and obtained 13789 BC pathology reports from all provinces in Iran in 2016. Pathology data, including tumor type, tumor site, tumor size, pathologic T stage, pathologic N stage, and tumor grade were examined for completeness by age group. Results: Pathology reports from 4000 women with BC in 2016 from across all provinces of Iran were selected for this study. The completeness of tumor type, tumor site, tumor size, pathologic T stage, pathologic N stage, and tumor grade increased with aging. In addition, the completeness of pathology reports varied across different variables. Accordingly, the tumor grade and pathologic T stage had the highest and lowest completeness rates (100 % versus 27.4%), respectively. Spatial analysis revealed significant high-risk areas for BC incidence, including Isfahan, Markazi, Chaharmahal and Bakhtiari, and Kohgiluyeh and Boyer-Ahmad provinces in central Iran. In contrast, North Khorasan was identified as a low-risk area. Conclusions: Considering the incompleteness of the pathology report in most of the tumor variables in the BC registry, we recognize the gaps to improve pathology data. To ensure effective interventions for BC control, tailored preventive measures are needed, particularly for high-risk areas. Continuous evaluation and data completion, including standard cellular pathology reports, are necessary for accurate BC control in Iran.
背景:乳腺癌(BC)是全世界妇女癌症相关死亡的主要原因,近年来其发病率在伊朗有所增加。目的:在本研究中,我们旨在评估基于人群的癌症登记系统中BC病理报告的完整性,并对2016年伊朗这种癌症的发病率进行空间分析,以帮助政策制定者制定有针对性的干预措施。方法:采用来自癌症综合信息管理系统(Integrated Cancer Information Management System)的二次数据,对2016年伊朗各省13789例BC病理报告进行回顾性描述性分析。病理资料包括肿瘤类型、肿瘤部位、肿瘤大小、病理T分期、病理N分期、肿瘤分级等,按年龄组进行完整性检查。结果:本研究选择了2016年来自伊朗所有省份的4000名BC女性的病理报告。肿瘤类型、肿瘤部位、肿瘤大小、病理T分期、病理N分期、肿瘤分级的完全性随年龄增长而增加。此外,病理报告的完整性在不同变量之间存在差异。因此,肿瘤分级和病理T分期的完成率最高和最低(分别为100%和27.4%)。空间分析显示,BC发病率高的地区包括伊朗中部的伊斯法罕、马卡齐、查哈尔马哈尔和巴赫蒂亚里,以及Kohgiluyeh和Boyer-Ahmad省。相比之下,北呼罗珊被确定为低风险地区。结论:考虑到BC登记中大多数肿瘤变量的病理报告不完整,我们认识到改进病理数据的差距。为了确保有效的BC控制干预措施,需要有针对性的预防措施,特别是在高风险地区。在伊朗,持续的评估和数据的完成,包括标准的细胞病理学报告,对于准确的BC控制是必要的。
期刊介绍:
International Journal of Cancer Management (IJCM) publishes peer-reviewed original studies and reviews on cancer etiology, epidemiology and risk factors, novel approach to cancer management including prevention, diagnosis, surgery, radiotherapy, medical oncology, and issues regarding cancer survivorship and palliative care. The scope spans the spectrum of cancer research from the laboratory to the clinic, with special emphasis on translational cancer research that bridge the laboratory and clinic. We also consider original case reports that expand clinical cancer knowledge and convey important best practice messages.